- THE EPOCH TIMES - AUG 3, 2021 - TOM OZIMEK -
The Food and Drug Administration (FDA) has authorized a monoclonal antibody cocktail as a measure to prevent infection in some groups of people who were exposed to the CCP virus, the pathogen that causes COVID-19.
The FDA on Friday announced that it had revised its emergency use authorization (EUA) for REGEN-COV, a treatment consisting of jointly administered casirivimab and imdevimab, expanding its use beyond just the treatment of patients who test positive for the virus.
While the product remains authorized for treating confirmed COVID-19 patients over age 12 who are at high risk of severe illness, the agency said the drug combo can now be given to high-risk groups as a measure after exposure to prevent progression of the disease.
The antibody treatment is only authorized for use in people who have been exposed to the CCP (Chinese Communist Party) virus, not as a pre-exposure preventive measure, the FDA said.
The agency added that REGEN-COV should only be used as a post-exposure prophylaxis by people who are not fully vaccinated or whose immune systems are unlikely to mount an adequate response to the virus, like those who take immunosuppressive medications or who are otherwise immunocompromised.
“Prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19,” the FDA noted, while urging people to get the shot.
LEIA MAIS:
Para acessar o Conteúdo acima, acesse a Home Page aqui. https://www.heitordepaola.online/